Ajanta Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.77×	0.77×	0.73×	0.79×
	1.12×	1.13×	1.07×	1.07×	1.14×
	24.2%	22.4%	24.0%	24.6%	17.4%
	0.98×	0.98×	0.96×	0.90×	0.86×
	1.32×	1.36×	1.32×	1.30×	1.38×
	26.3%	25.8%	25.2%	22.7%	18.7%
	25.4%	25.4%	25.0%	23.5%	17.7%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AJANTPHARM₹3,459.70

Ajanta Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹43,367 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.79	0.73	0.77	0.77	0.75
Interest Burden (Pretax/EBIT) ×	1.14	1.07	1.07	1.13	1.12
EBIT Margin %	17.43	24.63	24.00	22.40	24.22
Asset Turnover ×	0.86	0.90	0.96	0.98	0.98
Financial Leverage (Assets/Equity) ×	1.38	1.30	1.32	1.36	1.32
ROE (5-step product, year-end total equity) %	18.66	22.69	25.15	25.80	26.33
ROE (owners' profit / average owners' equity) %	17.68	23.49	25.02	25.39	25.39

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.